Skip to content
Tesla Inc (TSLA) has met with officials from a district in the city of Chongqing in southwestern China to discuss “accelerating projects”, the Liangjiang New Area said on Tuesday, as reported by Reuters.According to the report, officials held meetings with Tesla Vice-president Tao Lin, whose visit was reportedly welcomed by government official Duan Chenggang to “promote cooperation.”Reuters also reports unidentified sources cited by the China Securities Journal stating that cooperation could refer to sales and maintenance centers rather than factories. Last year Tesla opened its first plant outside the US in Shanghai.Shares in Tesla are climbing 6% in Tuesday’s pre-market trading, with the electric vehicle maker now up a whopping 265% year-to-date. The rally has continued unabated following strong second-quarter car deliveries, which exceeded analysts’ expectations. It delivered about 90,650 vehicles during the quarter, easily beating the estimated 74,130 figure.Piper Sandler analyst Alexander Potter has just boosted his price target on Tesla to $2,322 from...
Billionaire investor Bill Gross is predicting that value stocks like IBM and Altria Group are likely to fare better than growth stocks like Apple or Amazon.com in the near term, due to a correlation with real interest rates. U.S. real yields - which adjust for inflation - have been declining in response to the Federal Reserve's aggressive monetary actions over the past few months to limit the economic fallout of the coronavirus pandemic. Gross, who co-founded Pacific Investment Management Company, then spent four years at Janus Henderson before leaving in 2019 to manage his own money, said that the reason that the "Fab 5 stocks" and growth stocks in general had done "so fabulously well" centers on falling real interest rates that "are still reaching historic lows."...
Biogen (BIIB), in collaboration with Eisai, and the Alzheimer’s Clinical Trials Consortium, has initiated a new global Phase 3 clinical study (AHEAD 3-45) with BAN2401, an anti-amyloid beta (Aβ) protofibril antibody.The study will evaluate the therapeutic effect of BAN2401 on the progression of Alzheimer’s disease in individuals in preclinical (asymptomatic) stages of the disease. These patients are clinically normal and have intermediate or elevated levels of amyloid in their brains.The AHEAD 3-45 program consists of two trials, A3 and A45, which aim to evaluate the potential of BAN2401 to reduce accumulation of harmful amyloid beta aggregates in the brain and prevent cognitive decline due to Alzheimer’s disease.A total of 1400 participants will be enrolled in the study, and will be conducted in the US, Canada, Japan, Australia, Singapore and Europe.The A3 trial will enroll participants with an intermediate amount of amyloid in the brain and high risk for further amyloid beta accumulation, and thus at risk for...
